Besides the hallmark motor symptoms (rest tremor, hypokinesia, rigidity, and postural
instability), patients with Parkinson's disease (PD) have non-motor symptoms, namely …

Anxiety is a severe problem for at least one-third of people living with Parkinson's disease
(PD). Anxiety appears to have a greater adverse impact on quality of life than motor …

Levodopa (L-DOPA) treatment in Parkinson's disease is limited by the emergence of L-
DOPA-induced dyskinesia. Such dyskinesia is associated with aberrant gene regulation in …

Methylphenidate (MPH) is a dopamine transporter (DAT) inhibitor used to treat attention-
deficit/hyperactivity-disorder (ADHD). ADHD patients make impulsive choices in delay …

Parkinson's disease (PD) is a common chronic progressive multifactorial neurodegenerative
disease. In most cases, PD develops as a sporadic idiopathic disease. However, in 10 …

Background Dopaminergic and serotonergic degenerations alter pharmacological
neurotransmission and structural markers in Parkinson's disease (PD). Alteration of diffusion …

Homochiral (R)-and (S)-3, 4-methylenedioxymethamphetamine (MDMA) were prepared in
six steps (each) from the chiral pool precursors d-and l-alanine, respectively. The key step …

Numerous clinical studies have shown that the serotonergic system also degenerates in
patients with Parkinson's disease. The causal role of this impairment in Parkinson's …

Introducción: La discinesia representa la complicación motora más común de la
farmacoterapia con levodopa. La mayoría de los pacientes con Parkinson tienden a …

The role of pallidal serotonergic terminals in the development of L-Dopa-induced
dyskinesias (LIDs) in Parkinson's disease (PD) has been recently highlighted correlating …